| CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版） |
| |
| 引用本文： | 中国前列腺癌研究协作组（CPCC）,叶定伟,黄健. CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版）[J]. 中国癌症杂志, 2022, 32(12): 1242-1258. DOI: 10.19401/j.cnki.1007-3639.2022.12.013 |
| |
| 作者姓名： | 中国前列腺癌研究协作组（CPCC） 叶定伟 黄健 |
| |
| 作者单位： | 1.复旦大学附属肿瘤医院泌尿外科,复旦大学上海医学院肿瘤学系,上海 2000322.中山大学孙逸仙纪念医院泌尿外科,广东 广州 510060 |
| |
| 摘 要： | 转移性激素敏感性前列腺癌（metastatic hormone-sensitive prostate cancer,mHSPC）是需要持续关注的男性健康问题。2021年国内外各大指南关于mHSPC初始系统治疗推荐进行了重要更新,新型内分泌治疗（novel hormone therapy,NHT）联合雄激素剥夺治疗（androgen deprivation therapy,ADT）成为最重要的系统治疗方案。同时转移性前列腺癌原发灶局部治疗、转移灶定向治疗（metastasis-directed therapy,MDT）、基因检测、新型影像学（next-generation imaging,NGI）等新技术、新理念快速发展,推动mHSPC全程诊疗格局进一步改变。中国与欧美地区前列腺癌在遗传背景、早筛开展、初诊疾病分布及临床表现等方面均存在明显差异,为解答中国mHSPC临床管理相关的热点及争议问题,由中国前列腺癌研究协作组（Chinese Prostate Cancer Consortium,CPCC）组织多学科专家筛选关键决策问题,结合最新发表数据,经过多轮投票及讨论,最终形成《CPCC晚期前列腺癌中国专家共识——转移性激素敏感性前列腺癌起始应用新型内分泌治疗的全程管理（2022年版）》,以期为mHSPC真实世界临床管理提供决策参考。
|
| 关 键 词： | 转移性激素敏感性前列腺癌 新型内分泌治疗 全程管理 精准诊断 多模式治疗 |
| 收稿时间： | 2022-10-14 |
Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition) |
| |
| Chinese Prostate Cancer Consortium ,YE Dingwei,HUANG Jian. Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)[J]. China Oncology, 2022, 32(12): 1242-1258. DOI: 10.19401/j.cnki.1007-3639.2022.12.013 |
| |
| Authors: | Chinese Prostate Cancer Consortium YE Dingwei HUANG Jian |
| |
| Affiliation: | 1. Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China2. Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China |
| |
| Abstract: | Metastatic hormone-sensitive prostate cancer (mHSPC) is a male health concern requiring continuous attention. In 2021, an important update was included in domestic and international guidelines regarding the recommendations of initial systemic therapy for mHSPC, in which androgen deprivation therapy (ADT) combined with novel hormone therapy (NHT) has became the most important systemic treatment strategy. Meanwhile, emerging technologies and concepts, such as local therapy for the primary tumor in mHSPC, metastasis-directed therapy (MDT), genetic testing, and next generation imaging (NGI), have developed rapidly to promote further changes in the pattern of diagnosis and treatment of mHSPC. There are significant differences observed between China and western countries including genetics, screening policy, disease stage distribution and clinical characteristics at diagnosis. Focus on the controversial issues related to the clinical management of mHSPC in China, Chinese Prostate Cancer Consortium (CPCC) organized multidisciplinary experts to screen key decision-making questions based on the latest evidence. After multiple rounds of voting and discussion, the “Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)” is finally formed, aiming to provide a decision-making reference for clinical management of mHSPC in the real-world. |
| |
| Keywords: | Metastatic hormone-sensitive prostate cancer Novel hormone therapy Clinical management Precise diagnosis Multi-model therapy |
|
| 点击此处可从《中国癌症杂志》浏览原始摘要信息 |
|
点击此处可从《中国癌症杂志》下载全文 |
|
